WEST PALM BEACH, FL--(Marketwire -09/26/11)- Techs Loanstar, Inc. (OTCQB: TCLN.PK - News) (Pinksheets: TCLN.PK - News) and Quture, Inc. ("Quture") are providing a comprehensive shareholder update, in conjunction with the filing of its Super 8-K by Form 8-K/A, which details its future plans for making the company a success.
To our shareholders and supporters,
Quture is an emerging healthcare knowledge solution company created to transform health and healthcare by developing the standard in measuring clinical performance and outcomes. Quture provides healthcare organizations, insurers, government, private sector payers and related operators within the healthcare community with performance and outcomes measurement tools. The resources we have and will continue to develop are truly transformative tools to reduce medical costs while improving care and productivity in the practice of medicine. The Company's products focus on using actual clinical data from existing electronic databases to measure performance and outcomes by applying widely-accepted analytics.
Our management team holds more than 35 years of experience with a long history of working with many of the nation's leading healthcare institutions as leaders and innovators in measuring clinical performance. This experience, expertise, and developed clinical content will empower Quture to introduce products that have the potential to make value a factor in healthcare quality based on actual costs of delivering medical services, combined with performance and outcome measurement.
Our technology is enhanced through our application partnership with InterSystems Corporation, whose technology is implemented in 80% of hospitals throughout the United States. Through this collaboration, Quture has developed a technology platform that integrates clinical data from existing disparate electronic data sources in healthcare organizations. With the support of Ensemble, InterSystems' data integration product -- which is universally compatible with every electronic medical record (EMR) platform and database -- Quture quickly and effectively collects and integrates performance metrics into a proprietary database. As you read this, we are in the process of enhancing and integrating Quture's fully developed and existing products on to the InterSystems technology platform.
Quture's clinical content consists of evidence-based optimal clinical processes and clinical performance measures that were continuously refined and developed -- through external peer review -- for 35 years. Quture intends to license its transformative and disruptive technology through relationships with its customers. The Company also intends to accelerate its growth and revenues through mergers and acquisitions. Our existing relationships provide the Company with unique business opportunities for such opportunities.
We believe the Company's products and services will become an essential technology to improve healthcare, reduce costs and enhance the health of patients everywhere. Our initial target market includes hospitals, hospital systems and their insured trusts, as well as health maintenance organizations, physician groups, and provider groups (collaborative). Initial operations and sales will be structured through traditional licensing models. In the future, we plan to rapidly expand our product line toward patients and payers, further leveraging our clinical performance knowledge and databases for the benefit of all. Regional Health Information Exchanges are also a target customer for the InterSystems HealthShare product and should be considered a potential customer by Quture as well.
Our aim is to become the international standard in healthcare performance and outcomes measurement. We believe that performance measurement will become the new foundation upon which providers are reimbursed, granted privileges to practice in hospitals, and in the near future, selected by patients for their care.
Operationally, the Company will provide performance measures for customer selection from the QuOp Performance Measures Library. The metrics of numerator and denominator integration using the Ensemble interface engine will be installed in coordination with InterSystems engineers and support for the product will be primarily with InterSystems and supported in an advisory capacity by Quture.
We intend to introduce the Company's QualOptima performance measurement product into the market once we complete its planned demonstration with InterSystems at the University of Miami. After successful demonstration, QualOptima will be formally launched and then commercialized. At present, we are in the process of expanding the demonstration from anesthesiology to more than 40 other medical specialties.
The Company plans to negotiate contracts and licenses to install QualOptima in approximately ten (10) additional "pioneer" hospitals during this phase. The second three (3) month phase will be used to commence sales and marketing of the QualOptima product as we focus on existing strong relationships with major hospital corporations including their self-insured trusts at flagship hospitals. Once established, we will evolve our strategy and focus on selling to larger hospital systems and focus on specific product components including the relationship between performance and outcomes measures, natural language processing software components, aggregated medical specialties and specific federal initiatives such as re-hospitalizations and hospital acquired conditions. Once the two phases mentioned above are complete, Quture clients will be carefully coordinated with InterSystems.
The Company is also partnering with prominent national healthcare law firms and accounting firms as we leverage their representation and influence among hospital boards and other senior decision makers. At present we're conducting summit meetings for law and accounting firm clients as we educate them on upcoming compliance mandates and the risk of negligent credentialing.
QSurg is our company's surgery center electronic medical record (EMR) with a simplified QualOptima ("QuOp") performance analytics application. We anticipate marketing and sales of the QSurg product (6) months after commencement of marketing and sales of QualOptima. The QSurg product is designed for physician office surgical/invasive procedure facilities, ambulatory surgery centers, and surgical hospitals.
New federal incentives have created new health care organizational models that may also be targets for Quture products. First and foremost important among these are Accountable Care Organizations (ACOs). New regulations creating Health Homes where payments are bundled and divisible between providers based on performance and results for value are also important targets once we further establish ourselves. State cooperative insurance exchanges are another example of potential customers as are purchasers working with the federal government to employers to health savings accounts.
Finally, we intend to offer Quture to patients as well. Data sets and clinical knowledge, including predictive clinical and personalized data are valuable resources for any patient determining their path of care. As performance results become transparent and medicine becomes more personalized, participatory and predictive, performance measurement will evolve as customers seek to leverage the Good Clinical Practice (GCP) applications of Quture's products as they make critical decisions involving pharmaceutical and stem cell companies, medical device, equipment and supply manufacturers.
We look forward to the future with enormous enthusiasm. A copy of our most recent complete SEC filing can be viewed here:
G. Landon Feazell, CEO
Quture, Inc., a Nevada corporation, is positioned to rapidly become the international standard in healthcare performance and outcomes measurement and analytics to accomplish its corporate mission. Quture provides healthcare organizations, insurers, government payers, and other stakeholders in the healthcare community with performance measurement tools and data sets. Industry experts agree that performance and outcomes measurement is the "transformative tool" to reduce medical cost and improve quality of care. Quture's management team has 35 years of experience and a long history of working with many of the nation's leading healthcare institutions as a leader and innovator in measuring clinical performance. Quture is now testing its revolutionary solution to effectively and efficiently measure clinical performance from multiple vendor databases.
This release contains forward-looking statements, including, without limitation, statements concerning our business and possible or assumed future results of operations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including: our ability to continue as a going concern, adverse economic changes affecting markets we serve; competition in our markets and industry segments; our timing and the profitability of entering new markets; greater than expected costs, customer acceptance of our products or difficulties related to our integration of the businesses we may acquire; and other risks and uncertainties as may be detailed from time to time in our public announcements and SEC filings. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and our future results, levels of activity, performance or achievements may not meet these expectations. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law.
Constellation Asset Advisors, Inc.
+1 (415) 524-8500
For Media and Public Relations:
Propheta Communications, Inc